Business
Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million
Full-year revenues increased 65% to $44.5 million Investments in technology and staff position Sensus for growth in 2023 and beyond Conference call begins at
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"Full-year revenues increased 65% to $44.5 million Investments in technology and staff position Sensus for growth in 2023 and beyond Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions (Company or Sensus), announces financial results for the three and 12 months ended December 31, 2022. Highlights from the fourth quarter of 2022 and recent weeks include the following (all comparisons are with the fourth quarter of 2021, unless otherwise indicated): Revenues were $13.1 million, compared with $13.0 millionNet income was $2.8 million, or $0.17 per diluted share, compared with $5.3 million, or $0.32 per diluted shareEnded the quarter with $25.5 million in cash and cash equivalents, and no debtAdjusted EBITDA, a non-GAAP financial measure, was $4.3 million, compared with $5.6 millionShipped nine TransDermal Infusion Systems™ (TDI) to Hair Enhancement Centers for needleless injections of U.SK Under Skin’s hair-growth serum Skin Savers Hair™Introduced the Silk™ laser hair removal system with blended wavelengths for all skin phototypes at the Fall Clinical Dermatology ConferenceTwo key opinion leaders presented research on TDI to deliver finasteride for hair growth and onabotulinumtoxinA for hyperhidrosis at the Fall Clinical Dermatology ConferencePrepared for future growth with management promotions and hires in all operational areasPlans to submit several 510(k) applications to the U.S. Food and Drug Administration (FDA) in 2023 for aesthetic productsExpects continued topline growth in the first quarter of 2023 and full-year profitability Management Commentary “During the fourth quarter we executed well on our strategy and once again delivered strong revenues and profits,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We took a number of steps to position Sensus for future success. These included assembling the staff and strategies to drive sustainable and consistent growth, building inventory, acquiring new aesthetic products that will be submitted to FDA for anticipated clearance in the latter half of 2023, further investing in our Sentinel™ IT...